Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4

Xenobiotica

Volumn 42, Issue 7, 2012, Pages 633-640

  Ohbuchi, Masato ^a   Noguchi, Kiyoshi ^a   Kawamura, Akio ^a   Usui, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Clopidogrel; Esomeprazole; Famotidine and histamine H2 receptor antagonist; Lansoprazole; Omeprazole; Pantoprazole; Rabeprazole

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DRUG METABOLITE; ESOMEPRAZOLE; FAMOTIDINE; KETOCONAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INTERACTION; HUMAN; LIQUID CHROMATOGRAPHY; METABOLIC ACTIVATION; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FAMOTIDINE; HUMANS; OXIDOREDUCTASES, N-DEMETHYLATING; PROTON PUMP INHIBITORS; RECOMBINANT PROTEINS; TICLOPIDINE;

EID: 84861891333     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.653655     Document Type: Article

References (39)

1. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF; ACCF/ ACG/AHA. (2010). ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 122:2619-2633.
2. Andersson T, Andrén K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. (1990a). Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 39:51-54.
3. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P. (1990b). Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 47:79-85.
4. Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, Bergougnan L, Perrin L, LaCreta FP, Hurbin F, Dubar M. (2011). Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 89:65-74.
5. Aoyama K, Yoshinari K, Kim HJ, Nagata K, Yamazoe Y. (2009). Simultaneous expression of plural forms of human cytochrome P450 at desired ratios in HepG2 cells: adenovirus-mediated tool for cytochrome P450 reconstitution. Drug Metab Pharmacokinet 24:209-217.
6. Boulenc X, Djebli N, Shi J, Perrin L, Brian W, Van Horn R, Hurbin F. (2012). Effects of omeprazole and genetic polymorphism of cyp 2c19 on the clopidogrel active metabolite. Drug Metab Dispos 40:187-197.
7. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, Salazar DE. (2007). Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 81:735-741.
8. Furuta T, Iwaki T, Umemura K. (2010). Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 70:383-392.
9. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J. (2008). Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256-260.
10. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, Tonn GR, Van Horn R, Wang RW, Wong YN, Yang TJ, Obach RS. (2009). The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37:1355-1370.
11. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, OGara P, Whitlow P; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. (2007). Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115:813-818.
12. Howden CW, Tytgat GN. (1996). The tolerability and safety profile of famotidine. Clin Ther 18:36-54; discussion 35.
13. Hulot JS, Wuerzner G, Bachelot-Loza C, Azizi M, Blanchard A, Peyrard S, Funck-Brentano C, Gaussem P. (2010). Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects. J Thromb Haemost 8:610-613.
14. Humphries TJ, Merritt GJ. (1999). Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 13 Suppl 3:18-26.
15. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A. (2010). Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92-99.
16. Li XQ, Andersson TB, Ahlström M, Weidolf L. (2004). Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32:821-827.
17. Locniskar A, Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI. (1986). Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists. J Clin Pharmacol 26:299-303.
18. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. (2009). Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362.
19. Nagata K, Yamazoe Y. (2002). Genetic polymorphism of human cytochrome p450 involved in drug metabolism. Drug Metab Pharmacokinet 17:167-189.
20. Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, Ikeda T. (2009). Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xenobiotica 39:836-843.
21. Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P, Parkinson A. (2011). The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolismdependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos 39:2020-2033.
22. Parkinson A, Kazmi F, Buckley DB, Yerino P, Paris BL, Holsapple J, Toren P, Otradovec SM, Ogilvie BW. (2011). An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes. Drug Metab Dispos 39:1370-1387.
23. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, Picard C. (2002). Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30:1288-1295.
24. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM. (2000). Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891-896.
25. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schömig A, Kastrati A, von Beckerath N. (2009). Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101:714-719.
26. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. (2009). Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157:148.e1-148.e5.
27. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. (2009). Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363-375.
28. Siriswangvat S, Sansanayudh N, Nathisuwan S, Panomvana D. (2010). Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel. Circ J 74:2187-2192.
29. Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ. (2008). Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 48:475-484.
30. Taha AS, McCloskey C, Prasad R, Bezlyak V. (2009). Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, doubleblind, placebo-controlled trial. Lancet 374:119-125.
31. Takahashi M, Pang H, Kawabata K, Farid NA, Kurihara A. (2008). Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm Biomed Anal 48:1219-1224.
32. Tanaka M, Yamazaki H, Ryokawa Y, Hakusui H, Nakamichi N, Sekino H. (1996). Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers. Int J Clin Pharmacol Ther 34:415-419.
33. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, Yang D, Shi D, Yan B. (2006). Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467-1476.
34. Wilkinson GR, Guengerich FP, Branch RA. (1989). Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43:53-76.
35. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. (1997). Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283:434-442.
36. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. (1995). Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4?-hydroxylation status. Clin Pharmacol Ther 58:143-154.
37. Yasumori T, Li QH, Yamazoe Y, Ueda M, Tsuzuki T, Kato R. (1994). Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4?-hydroxylation. Pharmacogenetics 4:323-331.
38. Zahno A, Brecht K, Bodmer M, Bur D, Tsakiris DA, Krähenbühl S. (2010). Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. Br J Pharmacol 161:393-404.
39. Zhang H, Ragueneau-Majlessi I, Levy RH. (2009). Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition. Drug Metab Lett 3:287-289.